CVC Technologies Inc

CVC Technologies Inc has a market capitalization of TWD 1.71 billion and a price-to-earnings ratio of 12.64, which is below the industry median of 15.00. The company's price-to-book ratio of 1.31 is in line with the industry median of 1.30, indicating a relatively fair valuation of its book value. The enterprise value to EBITDA ratio of 14.95 is slightly above the industry median of 14.00, suggesting a moderate premium to earnings. The company's profitability metrics show a return on equity of 10.38% and a return on assets of 6.30%, both of which are below the industry medians of 12.00% and 7.50%, respectively. This indicates that CVC Technologies Inc is underperforming its peers in terms of capital efficiency and asset utilization. The gross profit margin of 44.27% is in line with the industry median of 44.00%, but the operating margin of 10.15% is below the industry median of 12.00%, suggesting higher operating costs relative to revenue. CVC Technologies Inc's revenue is concentrated in three key markets: America, India, and Mainland China. The company's geographic exposure is not disclosed in terms of revenue percentages, but the concentration in these regions may expose it to regulatory and economic risks specific to these markets. The company does not disclose segment-specific revenue figures, making it difficult to assess the contribution of different product lines to overall performance. The company's growth trajectory is modest, with a current FY revenue outlook of 4.5% growth and a next FY outlook of 3.0% growth. This is below the industry median of 6.0% for the current FY and 5.0% for the next FY. The company's capital expenditure of TWD -83.67 million indicates a reduction in investment, which may affect long-term growth potential. The free cash flow of TWD 73.49 million is positive but lower than the industry median of TWD 100.00 million, suggesting limited capacity for reinvestment or shareholder returns. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The debt-to-equity ratio of 0.37 is below the industry median of 0.50, indicating a conservative capital structure. However, the company has a negative net cash position after subtracting total debt, which may limit its ability to fund operations or investments without external financing. The risk assessment does not identify any significant regulatory or geopolitical risks, but the company's exposure to pharmaceutical markets may be affected by changes in healthcare regulations. Recent events include analyst estimates that suggest a mean price target of TWD 37.50, which is a 15.74% increase from the current market price of TWD 32.40. The mean recommendation of 1.67 indicates a generally positive outlook from analysts, with one strong buy, two buy, and no hold ratings. The company has not disclosed any recent filings or transcripts that would provide additional insight into its operations or strategic direction.